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Abstract: Lysophosphatidic acid (LPA), which is proposed to play an important role in 
normal physiological situations such as wound healing, vascular tone, vascular integrity 
and reproduction, may be involved in the etiology of some diseases such as atherosclerosis, 
cancer,  obesity  or  myocardial  infarction.  Abnormal  findings,  including  silent  brain 
infarction (SBI), are frequently observed by magnetic resonance imaging (MRI) in patients 
with  nonvalvular  atrial  fibrillation  (NVAF).  However,  whether  there  is  a  relationship 
between LPA level and the prevalence of SBI has not been extensively studied. In the 
present study, the association between them was investigated. 235 patients with NVAF, 
116 cases of SBI without NVAF and 120 cases of healthy volunteers (control group), who 
did not receive any antithrombotic therapy, were enrolled in this study. Plasma LPA levels 
in  the  NVAF  with  SBI  group  were  significantly  higher  than  that  in  the  control  group  
(p < 0.01), NVAF without SBI group (p < 0.01) and SBI without NVAF group (p < 0.01). 
The LPA levels are lower in the control group than in the NVAF without SBI and SBI 
without NVAF groups (p < 0.01), however, the latter two groups did not significantly differ 
from each other for LPA levels (p > 0.05) There were significant differences in the positive 
rate  of  platelet  activation  between  each  of  the  groups  (p < 0.01).  The  positive  rate  of 
platelet activation was significantly higher in the NVAF with SBI group. We suggest that 
LPA might be a novel marker for estimation of the status of platelet activation and the risk 
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factor for SBI onset in NVAF patients. We expected that plasma LPA levels could predict 
the occurrence of SBI in NVAF patients. 
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1. Introduction 
Atrial fibrillation (AF) is the most common sustained arrhythmia and its incidence increases with 
age [1,2]. The incidence of stroke increased by 5–7 times in patients with AF in contrast to that with no 
AF [3,4]. Therefore, it seems particularly important to explore the mechanism of emboli formation in 
non-valvular  atrial  fibrillation  (NVAF)  patients.  Previous  studies  mainly  concentrated  on  the 
coagulation and fibrinolytic functions. However, few studies have addressed the platelet activation 
state in patients with NVAF in vivo since there are few molecular markers which can effectively reflect 
the platelet activation in vivo [5]. In recent years, studies have found that lysophosphatidic acid (LPA), 
as a multifunctional “phospholipid messenger”, is mainly produced by activated platelets and may be 
an ideal molecular marker [6,7] reflecting platelet activation state in vivo. Platelets contribute to the 
production of LPA [8], which has been proposed to be a primary lipid in atherosclerotic plaque that is 
responsible for platelet activation [9]. LPA is also abundant in human atherosclerotic plaques, where it 
is thought to be derived, at least in part, from mild oxidation of low density lipoproteins [10]. Platelet 
depletion  or treatment  with  anti-platelet agents  reduces  circulating LPA levels in animals [11,12]. 
Hence, anti-thrombotic therapy targeting LPA production or receptor-mediated signaling may be a 
novel strategy to prevent thrombus formation. Silent brain infarction (SBI), which increases vascular 
cognitive impairment and stroke risk, has a high incidence in elderly people [13,14]. The occurrence of 
stroke  in  patients  with  NVAF  is  likely  preceded  by  subclinical  cerebrovascular  disease.  Many 
potentially abnormal findings, including the presence of SBI, which is detectable with brain magnetic 
resonance  imaging  (MRI),  have  been  recognized  in  patients  without  clinically  apparent  previous 
cerebrovascular  accidents  [15–17].  Despite  their  high  prevalence  and  clinical  significance,  the 
pathogenesis of silent ischemic lesions still remains elusive, especially in patients with NVAF [18]. 
There is consensus that it is high in elderly subjects and patients with risk factors for stroke such as 
hypertension,  age  and  AF  [16,19].  As  with  coronary  artery  disease,  multiple  observational  or  
cross-sectional studies have shown a relationship between homocysteine (Hcy) and stroke [20–24]. In 
addition, a Japanese study found a relationship between Hcy and silent areas of infarction by MRI, that 
is  to  say,  patients  with  a  silent  stroke  also  had  high  Hcy  levels  [14].  Other  studies  reported  the 
incidence of SBI to be 2.5 to 4.5 times higher in hyperhomocysteinemia [14], which is an independent 
risk  factor  for  vascular  diseases  such  as  cerebrovascular  and  cardiovascular  diseases  [25,26]. 
Furthermore,  SBI  has  been  considered  as  a  risk  factor  for  brain  hemorrhage  and  symptomatic  
infarction [19]. Futoshi et al. [27] indicated that there was a significant association between plasma 
homocysteine level  and  the prevalence of SBI  in  hemodialysis patients with chronic renal failure. 
However,  the  significance  of  increased  plasma  LPA  with  SBI  in  NVAF  patients  has  not  been 
adequately investigated. We hypothesized that increased levels of LPA are associated with SBI in Int. J. Mol. Sci. 2010, 11                       
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NVAF  patients,  which  might  provide  basis  for  clinical  antithrombotic  therapy  targeting  LPA 
production and its clinical application.  
2. Results and Discussion 
2.1. Results 
2.1.1. Baseline Characteristics of the Study Groups 
The baseline characteristics of each gGroup are shown in Table 1. Clinical and laboratory data, 
including age, sex, the occurrence of hypertension, diabetes mellitus and hyperlipidemia, and smoking 
status were not different in the four groups. 
Table 1. Baseline characteristics of each group. 
Variable 
NVAF + SBI (+) 
(n = 74) 
NVAF + SBI (−) 
(n = 161) 
SBI + NVAF (−) 
(n = 116) 
Control 
(n = 120) 
p 
Age, years (mean + SD)  64.6 ±  6.5  65.6 ±  7.9  62.5 ±  7.6  66.9 ±  5.8  ns 
Male   39 (52.7%)  83 (51.6%)  65 (56.0%)  64 (53.3%)  ns 
Hypertension  38 (51.4%)  78 (48.4%)  59 (50.9%)   51 (42.5%)  ns 
Diabetes mellitus  17 (23.0%)  36 (22.4%)  25 (21.6%)  22 (18.3%)  ns 
Dyslipidemia  20 (27.0%)  40 (24.8%)  28 (24.1%)  26 (21.7%)  ns 
Smoking  13 (17.6%)  27 (16.7%)  20 (17.2%)  18 (15.0%)  ns 
Platelet count (× 10
9)  197.1 ±  38.7   180.3 ±  33.6  203.2 ±  40.5  190.4 ±  38.8  ns 
NVAF with SBI: NVAF + SBI (+); NVAF without SBI: NVAF + SBI (−); SBI without NVAF: 
SBI + NVAF (−). 
2.1.2. Comparison of Plasma LPA Levels between Different Groups 
Among 235 cases of NVAF, 74 cases with SBI, which were found in accordance with the diagnostic 
criteria mentioned above, accounted for 31.5%. Plasma LPA levels in the NVAF with SBI group were 
significantly higher than that in the control group (p < 0.01), NVAF without SBI group (p < 0.01) and 
SBI without NVAF group (p < 0.01). The LPA levels are lower in the control group than in the NVAF 
without  SBI  and  SBI  without  NVAF  groups  (p < 0.01).  However  the  latter  two  groups  were  not 
significantly different from each other for LPA levels (p > 0.05) (Figure 1). 
2.1.3. Incidence of NVAF with SBI 
There were 59 cases of NVAF with SBI out of 157 cases of NVAF in patients older than 60 years of 
age, which accounted for 37.6%. In contrast, there were 15 cases of NVAF with SBI in 78 cases of 
NVAF patients younger than 60 years of age, which accounted for 19.2%. For the control group, this 
percentage was 10.8%. However, adjusting for age, the difference in the incidences of SBI in patients 
with NVAF older than 60 years of age compared with control groups remained statistically significant 
(p < 0.01). Int. J. Mol. Sci. 2010, 11                       
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Figure 1. Comparison of LPA concentration (μmol/L) between the different study groups:  
(A)  NVAF  with  SBI;  (B)  NVAF  without  SBI;  (C)  SBI  without  NVAF;  (D)  Control.  
Data are presented as means ±  SEM. Columns relevant to each group bearing different 
superscripts (a, b or c) differ significantly (p < 0.01). 
 
2.1.4. Comparison in the Positive Rate of Platelet Activation 
The percentage of platelet activation classified into mild, moderate and severe degree in the NVAF 
with SBI group was 6.8%, 8.1% and 85.1% respectively. However these percentages were 46.0%, 
34.8% and 21.2%, respectively, in the NVAF without SBI group. In parallel, the data was 22.4%, 
12.1% and 65.5% in the SBI without NVAF group and 79.2%, 12.5%, 8.3% in controls. There was a 
significant difference in the positive rate of platelet activation in each group (p < 0.01). 
2.2. Discussion 
The atrium loses its effective systolic function and the blood clots in theleft atrium at AF. Due to 
endothelial dysfunction, platelet activation, coagulation and fibrinolytic activity being abnormal, the 
body  is  in  a  state  of  hypercoagulability  or  prethrombotic  and  the  left  atrium,  particularly  in  the  
left  atrial  appendage,  easily  form  mural  thrombus.  Once  the  thrombus  is  detached,  it  causes 
thromboembolic complications, especially ischemic stroke [14]. According to previous study, though 
platelet activation was not directly involved in thrombosis in AF, it could play an important role in 
blood hypercoagulability [28]. The data in the present study indicated that plasma LPA levels were 
significantly increased in NVAF patients with SBI. It revealed that platelet activation existed in these 
patients and that this activation might contribute to further LPA generation, which would activate more 
platelets to form emboli or emboli rain in turns. The emboli lead to SBI. Thus LPA can be used as a 
possible molecular marker for estimating thrombosis or prethrombotic status in patients with NVAF. Int. J. Mol. Sci. 2010, 11                       
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A  Japanese  community-based  study  reported  that  the  incidence  of  SBI  in  the  population  of  
66-year-old elderly was 24.8% [29], while the incidence of SBI in the population of 65-year-old elderly 
was 28% in a cardiovascular health study [30]. Our study found that the incidence of SBI in NVAF 
patients of 60-years-old was 37.6%, significantly higher than that in the age-matched control group 
(10.8%). However, the prevalence of SBI in patients with NVAF in our study is higher than that in the 
common population  [29]. It should be noted that this prevalence is related to the particular study 
subjects rather than true prevalence, because the present study has a possible selection bias inherent in 
this type of hospital-based study. The prevalence of SBI will be affected by the sensitivity of the 
examination technique and the composition of the study samples with regard to age, sex, race and 
vascular risk factors. In additional, some other serum markers such as homocysteine (Hcy) or brain 
natriuretic peptide (BNP), known to correlate with an increased incidence of SBI, might be involved in 
the alteration of LPA levels. Hyperhomocysteinemia also enhances platelet adhesion to endothelial 
cells,  promotes  growth  of  vascular  smooth  muscles  cells,  and  is  associated  with  higher  levels  of 
prothrombotic  factors  such  as  β-thromboglobulin,  tissue  plasminogen  activator  and  factor  VII 
coagulant (FVIIc) [27]. Although this issue was discussed controversially, previous study indicated that 
elevated  plasma  concentrations  of  BNP  were  associated  with  the  presence  of  AF  [31]  while  the 
associations  between  these  serum  markers  and  LPA  levels  had  not  been  fully  understood.  The 
additional further research on the role that the interaction between these serum markers such as LPA, 
Hcy and BNP played in the prevalence of the SBI was desirable. Furthermore, AF was one of the most 
important risk factors for SBI. So the frequency of SBI in the present study was relatively higher than 
that in previous reports mentioned above. Moreover, previous studies reported that an irregular heart 
rate blunted nitric oxide (NO) synthesis and increased p-selectin expression on platelets, ultimately 
increasing the risk for SBI [32,33]. Irregular shear stress upon the vascular endothelium in patients 
with AF also may cause sclerotic changes which contribute to the attenuation of NO synthesis [34,35]. 
This hypothesis is further supported by several reports that the prevalence of SBI lesions is associated 
with atherosclerosis related factors such as aging, diabetes mellitus and hypertension [36–39]. If the 
NO  attenuation  hypothesis  is  true,  the  higher  prevalence  of  SBI  in  the  NVAF  patients  may  be 
explained better. 
One  of  limitations  of  our  study  was  that  the  study  design  was  not  randomized.  Secondly,  an 
extension of the actual data by the determination of some additional already established markers for 
platelet  activation  such  as  granulocyte-colony  stimulating  factor  (G-CSF),  interleukin-6  and 
thrombopoietin (TPO), etc., might strengthen the result of this study. It was a pity that these markers 
were  not  determined  in  this  study.  Thirdly,  certain  diseases  may  influence activated LPA release, 
including inflammatory processes, hypercholesterolemia or diabetes mellitus. In additional, LPA was 
measured  after  SBI  onset  in  this  study.  Whether  high  LPA  can  be  a  risk  factor  for  SBI  needs  a 
prospective study. Future studies, therefore, need to include not only prospective or longitudinal LPA 
comparative  analyses  but  also  investigations  that  will  determine  whether  plasma  LPA  levels  are 
influenced by other medical conditions or biomarkers which affecting the production, secretion and 
circulation of LPA. Longitudinal studies are also required to assess how well LPA levels correlate with 
SBI and thus might be used as a marker for monitoring treatment, progression and recurrence.  
 Int. J. Mol. Sci. 2010, 11                       
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3. Materials and Methods 
3.1. Study Subjects 
Subjects enrolled in the study were informed and gave consent. The protocol of the study was 
approved by the local ethics committees. Patients were selected from 894 patients with NVAF who had 
been screened in outpatient clinics in four teaching hospitals. Of the 894 patients, 235 cases with 
NVAF and 116 cases of SBI without NVAF, who did not receive any antithrombotic therapy, were 
recruited as candidates for the present study. 120 cases of healthy volunteers older than 60-years of age 
(control  group)  were  enrolled  in  this  study.  The  controls  were  selected  by  the  same  experienced 
clinician and were subjected to neurological examination, and were neurologically normal adults in 
regard to sinus rhythm, recruited during routine health check-ups at the neurology outpatient clinic. All 
subjects enrolled in this study underwent echocardiography and ultrasonography of the carotid arteries. 
The  candidate  criterion  used  to  select  235  cases  with  NVAF  is  as  following:  (1)  Continuous  or 
intermittent  NVAF  in  patients  was  diagnosed  by  clinical  symptoms,  electrocardiogram,  cardiac 
ultrasound and so on; (2) Age varied from 45 to 85. Exclusion criteria: Patients with NVAF, who had 
any of the following illnesses, conditions or requirement: (1) Rheumatic or congenital valvular heart 
disease; (2) After heart valve replacement; (3) Congestive heart failure and severe heart diseases. The 
diagnosis of congestive heart failure and severe heart diseases was confirmed by a complete medical 
evaluation, medical history and physical examination as well as various tests including echocardiogram 
and a chest X-ray to detect abnormal function of the left ventricle and/or heart valves and the size and 
shape of the heart; (4) Coagulation abnormalities. Coagulation abnormalities was defined as an INR 
spontaneously >1.6 and/or an APTT >60 s and/or a platelet count <150 ×  10
9/L and/or a fibrinogen less 
than 1.0 g/L; (5) Intracranial or systemic infection; (6) Obvious organs dysfunction (such as liver, 
kidney, lung). The cut off values about organs dysfunction were shown in Table 2; (7) With previous 
history of stroke or transient ischemic attack (TIA); (8) Receiving antithrombotic or warfarin therapy; 
(9) Hypertension with carotid atherosclerosis or hemal stricture revealed by carotid color ultrasonic 
examination; (10) Female in the menstruation period. 116 cases of SBI without NVAF were selected 
from patients who were hospitalized with dizziness, headache, cervical spondylosis, lumbar spinal 
stenosis, intracranial infection, acute carbon monoxide poisoning, facial paralysis and so on. A normal 
neurological examination with no focal deficit at the time of entry was required. 120 healthy controls 
that had no history of cerebral or cardiac vascular diseases and no symptoms mentioned above within 
one month were matched to patients by age and gender.  
Information about clinical characteristics in each group such as arterial hypertension (AH), diabetes 
mellitus (DM), dyslipidemia and smoking habit were recorded. Cranial MRI was performed in all 
participants  at  entry  to  the  study.  Because  this  study  involved  multiple  institutions,  the  MRI 
instruments differed, and a magnetic field strength of 1.0 T or more was used at each institution. 
Almost all patients underwent MRI examination, except for two patients in the SBI group who had 
metal in their bodies, and were analyzed on the basis of cerebral computed tomography without MRI. 
All subjects were examined by the same investigator who was blinded to clinical characteristics. The 
diagnosis of SBI was made with reference to the criteria established by Matsui et al. [14,40]: (1) SBI 
was defined as an area (≥3 mm in diameter) of focal hyperintensity on T2-weighted images or FLAIR Int. J. Mol. Sci. 2010, 11                       
 
 
3994 
images with corresponding low signal intensity on T1-weighted images and low density lesions on CT; 
(2) Lack of evidences for the nervous system symptoms or signs which can be explained by lesions 
observed on MRI or CT; (3) Without a history of clinical stroke; (4) Patients with micro-bleeding or 
suspected bleeding followed by infarction were excluded by imaging. 
Table 2. The cut-off values for organ dysfunction. 
Variables  Cut off Values 
Respiratory, PaO2/FiO2 (mmHg)  ≤300 
Coagulation, platelets × 10
3/μmol  ≤150 
Liver, bilirubin (mg/dL)
a  ≥2.0 
Cardiovascular, hypotension  Mean arterial pressure <70 mmHg 
Renal creatinine (mg/dL)
b or 
Urine output (mL/d) 
Glomerular filtration rate (GFR) 
>2.0 or  
<500 mL 
≤70 mL/min 
a To convert bilirubin from mg/dL to μmol/L, multiply by 17.1; 
b To convert creatinine from mg/dL 
to μmol/L, multiply by 88.4. 
3.2. Sample Collection and LPA Analysis  
Patients were told to stay away from fatty food and alcohol for several days before fasting blood 
samples were obtained in the morning. We did not have blood drawn from women if they were in their 
menstruation  period.  Four  milliliters  of  venous  blood  was  drawn  from  each  participant  into 
commercially  available  anticoagulant  tubes  (Two-fish  Comp.).  Plasma  was  either  processed 
immediately or stored at −70 ° C before lipid extraction. Lipid extraction was performed at 0 ° C to 4 ° C 
to minimize damage to ester bonds, using a slight modification of published methods [41]. Whole 
blood was centrifuged at 3500 g for 10 minutes. The supernatant was transferred to a microcentrifuge 
tube and centrifuged at 8000 g for 10 minutes. Then 1 mL suspension (platelet-poor plasma) was used 
for  the  remaining  procedure.  Lipids  were  extracted  with  4  mL  of  1-butanol  and  2  mL  of  
water-saturated 1-butanol. The resulting organic extracts were pooled and dried in vacuo. Each sample 
was resuspended in 0.3 mL of chloroform/methanol/water/28% NH4OH (250:100:15:0.3, v/v) and was 
immediately  filtered  by  an  Econosphere  3  μm,  50  ×   4.6  mm  silica  column  (Alltech  Associates, 
Deerfield,  IL).  Compounds  were  eluted  with  a  mobile  phase  of  chloroform/methanol/water/28% 
NH4OH (250:100:15:0.3, v/v) at 0.5 mL/min. The source was maintained at 250 °C  with a drying gas 
flow  of  10  L/h.  The  concentration of LPA was  quantified by measuring its  inorganic phosphorus 
component using colorimetric assays. 
3.3. Estimation of Platelet Activation Degree 
Plasma LPA was considered to be a more sensitive and meaningful biomarker of platelet activation 
and LPA level could indirectly reflect the degree of platelet activation in vivo. The cut-off values for 
LPA levels were classified according to the degree of platelet activation in this study as follows: If the 
LPA concentration ≤3.0 μmol/L, platelet function was considered as being in a state of normal or mild 
activation; If LPA concentration >3.0 μmol/L, but ≤3.5 μmol/L, the platelet function was in moderate Int. J. Mol. Sci. 2010, 11                       
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activation state; LPA concentration >3.5 μmol/L, the platelet function was in a highly activated state or 
the formation of emboli. The data about the risk classification in respect to the LPA plasma levels is 
based on our previous study [42]. However, these cut-off values may be applicable only to this study 
population and will have to be reevaluated following larger studies. 
3.4. Statistical Analysis 
Comparisons of the baseline characteristics and observations in the present study were performed by 
ANOVA and univariate analysis with Student‟s t-test or Mann-Whitney‟s test for continuous variables 
and the Fisher exact test for noncontinuous variables. Chi-square test was used to analyze the incidence 
of SBI between the NVAF group and the control group. All statistical analyses were performed with 
SPSS software package for Windows version 11.5. Data was expressed as mean ±  SEM and statistical 
significance was set at p < 0.05. 
4. Conclusions  
Our data indicate that the plasma LPA levels significantly increased in NVAF or NVAF patients 
with SBI, which was accompanied by the high incidence of SBI. Based on the results presented here, 
we suggest that LPA might be a novel marker for estimation of the status of platelet activation and the 
risk factor for SBI onset in  NVAF patients.  We expect  that plasma LPA levels could predict the 
occurrence of SBI in NVAF patients. There may be a relationship between plasma LPA levels and the 
prevalence of SBI in NVAF patients. If the plasma LPA levels were not an independent predictor for 
SBI, its predicted significance may be limited and this data should be interpreted carefully because the 
present study was not designed to test the predictabilities of plasma LPA levels. However, our results 
warrant further study. This was also the first study to examine the association between plasma LPA 
levels  and  the  occurrence  of  SBI  in  NVAF  patients  and  it  might  be  an  important  subject  for 
randomized trials and prospective research for some years to come. 
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